EcoDrugPlus

Bcr Activator Of Rhogef And Gtpase

Ensembl ID : ENSOMEG00000021614
Gene Symbol: BCR
3 Cross references
196 Possible Orthologues:

Bdnf/nt-3 Growth Factors Receptor-Like

Ensembl ID : ENSOMEG00000010657
Gene Symbol: LOC112163033
3 Cross references
207 Possible Orthologues:

Bruton Tyrosine Kinase

Ensembl ID : ENSOMEG00000013982
Gene Symbol: BTK
1 Cross references
204 Possible Orthologues:

C-C Chemokine Receptor Type 9-Like

Ensembl ID : ENSOMEG00000002723
Gene Symbol: LOC112144346
3 Cross references
188 Possible Orthologues:

C-C Motif Chemokine Receptor 9

Ensembl ID : ENSOMEG00000001256
Gene Symbol: CCR9
3 Cross references
193 Possible Orthologues:

C-X-C Motif Chemokine Receptor 2

Ensembl ID : ENSOMEG00000009865
Gene Symbol: CXCR2
1 Cross references
275 Possible Orthologues:

C-X-C Motif Chemokine Receptor 4

Ensembl ID : ENSOMEG00000015896
Gene Symbol: CXCR4
3 Cross references
201 Possible Orthologues:

C-Reactive Protein-Like

Ensembl ID : ENSOMEG00000003630
Gene Symbol: LOC112144053
2 Cross references
400 Possible Orthologues:

C-Reactive Protein-Like

Ensembl ID : ENSOMEG00000003507
Gene Symbol: LOC112143814
2 Cross references
402 Possible Orthologues:

C-Reactive Protein-Like

Ensembl ID : ENSOMEG00000003595
Gene Symbol: LOC112143562
2 Cross references
400 Possible Orthologues:

C-Reactive Protein-Like

Ensembl ID : ENSOMEG00000003431
Gene Symbol: LOC112144004
2 Cross references
400 Possible Orthologues:

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSOMEG00000006105
Gene Symbol: CFTR
3 Cross references
214 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).